Intrigue Around FDA Decision on Cempra’s (CEMP) Antibiotic


Shares of Cempra, Inc. (Nasdaq:CEMP) are trading in negative territory by 3.63% (or -$0.22) at $5.97 on Tuesday, ahead of the U.S. Food and Drug Administration’s (FDA) target date to make an approval decision on the company’s solithromycin (December 27 and 28, 2016 for the oral and IV intravenous formulations, respectively).

Last month, an FDA panel voted (7-6) that efficacy results of solithromycin – a highly potent macrolide – outweighed its potential safety problems for the treatment of community-acquired bacterial pneumonia.

Cempra, which focuses on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases, has 52.38M shares outstanding and CEMP stock 52-week range is from $5.70 to $32.31 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at